| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsNCT06126380 | Eledon Pharmaceuticals | Phase 2 | Enrolling by invitation | 2029-12Estimated |
| A Study to Evaluate ARD-501 in Patients With Autism Spectrum DisorderNCT06126653 | AARD | Phase 2 | Completed | 2025-01-13Actual |
| A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)NCT06127043 | ANAB | Phase 2 | Active not recruiting | 2026-01Estimated |
| A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT06128369 | Oculis | Phase 3 | Terminated | 2024-05-02Actual |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)NCT06128629 | Intellia Therapeutics | Phase 3 | Recruiting | 2027-12Estimated |
| MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256 | Syndax Pharmaceuticals | Phase 2 | Completed | 2026-08-27Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741 | NKTR | Phase 2 | Active not recruiting | 2025-05-06Actual |
| Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613 | Vanda Pharmaceuticals | Phase 3 | Active not recruiting | 2027-09-30Estimated |
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918 | SKYE | Phase 2 | Completed | 2024-02-22Actual |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101 | Incannex Healthcare Ltd | Phase 2, Phase 3 | Completed | 2025-05-20Actual |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLNCT06149247 | Soligenix | Phase 2 | Completed | 2024-05-31Actual |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924 | MLYS | Phase 2 | Completed | 2025-02-27Actual |
| Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusNCT06152042 | BMEA | Phase 2 | Completed | 2025-05-20Actual |
| Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionNCT06152861 | Glaukos Corporation | Phase 2 | Unknown | 2024-08Estimated |
| Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 | MLYS | Phase 3 | Completed | 2024-12-10Actual |
| RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyNCT06154252 | Cabaletta Bio | Phase 2, Phase 3 | Recruiting | 2028-07Estimated |
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151 | PGEN | Phase 2 | Recruiting | 2026-11-11Estimated |
| ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 | ACAD | Phase 2, Phase 3 | Recruiting | 2028-01Estimated |
| Influenza Viral Challenge Study of CC-42344 in Healthy ParticipantsNCT06160531 | COCP | Phase 2 | Completed | 2024-05-03Actual |
| Study of Olutasidenib and Temozolomide in HGGNCT06161974 | Rigel Pharmaceuticals | Phase 2 | Recruiting | 2029-06Estimated |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 | RVMD | Phase 1, Phase 2 | Recruiting | 2027-06Estimated |
| A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABPNCT06162286 | Zai Lab (Hong Kong), Ltd. | Phase 3 | Unknown | 2025-01-01Estimated |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT06164704 | UPB | Phase 2 | Completed | 2025-07-07Actual |
| A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelNCT06170242 | ENTA | Phase 2 | Completed | 2024-06-17Actual |
| A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)NCT06172257 | Oculis | Phase 3 | Completed | 2026-04-02Actual |
| Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06173531 | ACAD | Phase 3 | Completed | 2025-08-19Actual |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 | LBRX | Phase 2 | Completed | 2024-12-04Actual |
| Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)NCT06181136 | DNLI | Phase 1, Phase 2 | Recruiting | 2032-07Estimated |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.NCT06185543 | NRSN | Phase 2 | Terminated | 2025-09-30Actual |
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT06190093 | OTLK | Phase 3 | Completed | 2024-11-07Actual |
Trial details
- Registry ID
- NCT06126380
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06126653
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06127043
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06128369
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06128629
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06132256
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06136741
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06138613
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06144918
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06146101
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06149247
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06150924
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06152042
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06152861
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06153693
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06154252
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06157151
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06159673
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06160531
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06161974
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06162221
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT06162286
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06164704
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06170242
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06172257
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06173531
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06179108
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06181136
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT06185543
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06190093
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.